Bon Natural Life Ltd (BON) stock

BONNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends September 30

Financials through fiscal 2025, year ended Sep 30, 2025Last filing: 20-F on Jan 23, 2026Score 0/30

$1.10−0.03 (-2.65%)

Close on Nov 13, 2026Market cap $8.94MP/E –Yield –

Bon Natural Life r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was $754.19K, down 53.5% from the year before. The highest annual figure on record is $1.62M in fiscal 2024.

Period	Period end	Value	Change
FY2025	Sep 30, 2025	$754.19K	-53.5%
FY2024	Sep 30, 2024	$1.62M	+443.0%
FY2023	Sep 30, 2023	$298.47K	-29.7%
FY2022	Sep 30, 2022	$424.56K	+70.5%
FY2021	Sep 30, 2021	$249.05K	+21.3%
FY2020	Sep 30, 2020	$205.36K	-60.7%
FY2019	Sep 30, 2019	$522.87K	–

Parsed from the XBRL in Bon Natural Life's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-25 reverse split on May 19, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BON.

Revenue growth-21.7% · median 8.5%

Gross margin20.8% · median 61.1%

Operating margin-8.7% · median -21.9%

Net margin-10.7% · median -14.0%

Advertisement
300 × 250

See a number that looks wrong?